Clinical Trials Logo

Leukemia, Myeloid clinical trials

View clinical trials related to Leukemia, Myeloid.

Filter by:

NCT ID: NCT02905994 Withdrawn - AML Clinical Trials

Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia

Start date: September 2016
Phase: Phase 1
Study type: Interventional

The study intervention involved in this study is the addition of a dose of volasertib as a part of the initial chemotherapy regimen for AML. The trial will involve a combination of the following drugs: - Volasertib (the study drug) - Idarubicin - Cytarabine

NCT ID: NCT02856178 Withdrawn - Clinical trials for Acute Myeloid Leukemia

Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients

SAFEGUARD
Start date: April 20, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This study assesses the pharmacokinetics and safety of the new antifungal F901318 in AML patients.

NCT ID: NCT02829840 Withdrawn - Leukemia Clinical Trials

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Start date: September 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of Part 1 of this clinical research study is to learn if ponatinib alone can help to control FLT3-mutated AML or FLT3-mutated high-risk MDS. The safety of this drug will also be studied. The goal of Part 2 of this clinical research study is to find the highest tolerable dose of ponatinib in combination with 5-azacytidine and to learn if the highest dose level found can help to control FLT3-mutated AML or FLT3-mutated high-risk MDS. The safety of this combination will also be studied.

NCT ID: NCT02826642 Withdrawn - Clinical trials for Acute Myeloid Leukemia (AML)

A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia

Start date: August 26, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and potential efficacy of IDH305 with standard treatments for newly diagnosed IDH1R132 mutant acute myeloid leukemia (AML).

NCT ID: NCT02791919 Withdrawn - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Start date: May 25, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of wee1 kinase inhibitor AZD1775 when given together with fludarabine, cytarabine, and filgrastim (FLAG) combination chemotherapy in treating children, adolescents and young adults with relapsed or refractory acute myeloid leukemia. Wee1 kinase inhibitor AZD1775 may help combination chemotherapy work better by making tumor cells more sensitive to the drugs. Drugs used in chemotherapy, such as fludarabine and cytarabine, may prevent tumor cells from multiplying by damaging their deoxyribonucleic acid (DNA), which in turn stops the tumor from growing. Giving wee1 kinase inhibitor AZD1775 and FLAG chemotherapy may work better in treating patients with acute myeloid leukemia.

NCT ID: NCT02765997 Withdrawn - Clinical trials for Acute Myeloid Leukemia

StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies

Start date: April 2017
Phase: Phase 2
Study type: Interventional

This is an open label, interventional, randomized phase II trial comparing StemRegenin-1 (SR-1) cultured umbilical cord blood (experimental arm) to unmanipulated umbilical cord blood (standard of care arm) transplantation after a myeloablative CY/FLU/TBI conditioning. A 2:1 randomization will be employed with a higher chance of being assigned to the experimental arm.

NCT ID: NCT02734823 Withdrawn - Clinical trials for Gastrointestinal Stromal Tumor

Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor

Start date: March 1, 2016
Phase:
Study type: Observational

This pilot research trial studies the long term effects of tyrosine kinase inhibitor therapy on ovarian reserve and fertility in patients with chronic myeloid leukemia or gastrointestinal stromal tumor. Studying ovary imaging, ovarian reserve markers, and hormone levels from patients receiving tyrosine kinase inhibitor therapy may help doctors learn more about the effects of tyrosine kinase inhibitor therapy on ovarian function and fertility.

NCT ID: NCT02723435 Withdrawn - Clinical trials for Adult Acute Myeloid Leukemia in Remission

Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant

Start date: n/a
Phase: Phase 2
Study type: Interventional

This phase 2 trial studies the side effects and how well midostaurin works in treating older patients with acute myeloid leukemia with change in genetic material post-hematopoietic cell transplantation. Midostaruin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving midostaruin post-transplant may improve patient outcomes.

NCT ID: NCT02722135 Withdrawn - Clinical trials for Leukemia, Myeloid, Acute

A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed

Start date: November 2016
Phase: Phase 1
Study type: Interventional

This is an open-label, dose-escalating trial to evaluate the MTD and/or dose to be used for further development by evaluation of DLT in course 1 and the safety of volasertib when added to standard intensive salvage chemotherapy with DNX-FLA in paediatric patients with AML after failure of first-line therapy. Furthermore, data on efficacy and PK/PD of volasertib in paediatric patients with AML when added to standard intensive salvage chemotherapy will be collected.

NCT ID: NCT02680951 Withdrawn - Clinical trials for Acute Myeloid Leukemia

Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

Start date: December 2015
Phase: Phase 1
Study type: Interventional

This study will examine the appropriate dose and side effects of dasatinib, when it is given with the standard of care chemotherapy for children and adolescents with Acute Myeloid Leukemia (AML).